Correction to “Benefit of axicabtagene ciloleucel vs chemoimmunotherapy in older patients and/or patients with poor <scp>ECOG</scp> performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy”

Authors:

Published: 0000-00-00

DOI: HTTPS://DOI.ORG/10.1002/ajh.27356

Keywords:

Abstract:

Source: